Welcome to our dedicated page for Hoth Therapeutics news (Ticker: HOTH), a resource for investors and traders seeking the latest updates and insights on Hoth Therapeutics stock.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for dermatological disorders and other significant medical needs. The company focuses on conditions such as eczema, chronic wounds, psoriasis, asthma, and acne. Utilizing their proprietary BioLexa Platform, Hoth Therapeutics aims to create two topical cream products to treat eczema and reduce post-procedure infections in aesthetic dermatology patients.
Hoth Therapeutics has established numerous license and partnership agreements with prestigious institutions including The George Washington University, The University of Maryland Baltimore, Isoprene Pharmaceuticals, Inc., North Carolina State University, Chelexa Biosciences, Inc., The University of Cincinnati, and Zyla Therapeutics, Inc. Notably, Hoth is co-developing a topical treatment with Zyla Therapeutics for cutaneous lupus erythematosus, an autoimmune disease that severely impacts patient quality of life.
The company’s research collaborations extend to various areas including HT-001, a potential treatment for cancer patients experiencing skin toxicities from Epidermal Growth Factor Receptor Inhibitors (EGFRI). Hoth has recently received FDA clearance to proceed with protocol amendments in its ongoing Phase 2a clinical trials for HT-001, aiming to optimize clinical outcomes.
Hoth Therapeutics has also made strides in Alzheimer's Disease research with its HT-ALZ project, targeting neuroinflammation and cognitive deficits by antagonizing the NK1 receptor. Pre-clinical research has shown promising results in improving cognitive functions among Alzheimer's patients.
In addition to their pipeline, Hoth's subsidiary Merveille.ai has been pivotal in advancing obesity treatment using artificial intelligence. The discovery of a promising new therapeutic candidate for obesity, leveraging large language model technologies, underscores their commitment to innovative health solutions.
Financially, Hoth Therapeutics recently engaged in an agreement to exercise warrants, raising approximately $4.2 million to support its working capital needs. Their strategic partnership with Venable, LLP further strengthens their intellectual property protection, vital for ongoing and future therapeutic developments.
Collaborations with Wise Systems International SRL and integration of the Nvidia BioNeMo AI platform are set to enhance Hoth's drug discovery capabilities, leveraging artificial intelligence for cutting-edge therapeutic advancements.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has requested a Pre-Investigational New Drug (IND) meeting with the FDA regarding HT-001, a topical treatment aimed at addressing skin disorders from epidermal growth factor receptor (EGFR) inhibitor therapy. Over 50% of cancer patients on EGFR inhibitors experience dermatological side effects, impacting their treatment. HT-001 seeks to improve these patients' quality of life. Currently in preclinical development, the company plans to discuss clinical trial designs in its upcoming FDA meeting scheduled for Q1 2021.
Hoth (NASDAQ: HOTH) has partnered with Zylö Therapeutics to co-develop a topical treatment for Cutaneous Lupus Erythematosus (CLE), utilizing a patented delivery system called Z-pods™. The drug HT-005, targeting the endocannabinoid pathway, showed proof-of-concept efficacy in reducing skin plaques during a study in MRL/MpJ-Faslpr/J mice. This collaboration aims to address the limited therapeutic options available for CLE, which significantly impacts patient quality of life.
Hoth Therapeutics (NASDAQ: HOTH) has secured Human Research Ethics Committee (HREC) clearance to initiate its Phase 1b clinical trial of BioLexa Lotion for treating mild to moderate atopic dermatitis in Australia. Dosing of the first subject is expected early 2021, with top-line data anticipated in Q1 2021. The trial aims to evaluate the safety and pharmacokinetics of BioLexa, with preliminary efficacy assessed in a second patient cohort. CEO Robb Knie emphasized the milestone as crucial for submitting data for future FDA considerations.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced promising preclinical data for its therapy HT-005 targeting Cutaneous Lupus Erythematosus (CLE). Conducted by Jackson Laboratory with Zylö Therapeutics, results showed a significant reduction in skin plaque severity in mice after using HT-005-loaded topical Z-pods™. Improvements were observed within 3 weeks and maintained through 10 weeks. CEO Robb Knie expressed optimism about the therapeutic's potential addressing a high unmet need in CLE.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced key milestones in its COVID-19 product development. The company is progressing with its HT-002 peptide therapeutic aimed at treating COVID-19 symptoms, with inhibition test data expected in December 2020. The On-the-Go SARS-CoV-2 Testing Device is in research, aiming for proof-of-concept data by year-end 2020. Additionally, the VaxCelerate vaccine platform shows promise in animal models, with further preclinical studies planned. Hoth is focused on rapid development to address critical medical needs in COVID-19.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced the granting of U.S. Patent No. 10,793,525 for novel 13-Cis-RAMBA retinamides aimed at targeting cancer-associated signaling pathways. This first-of-its-kind patent expires on October 5, 2036. The compounds are designed to disrupt the MNK1/2-driven signaling pathway linked to various cancers, including breast and prostate cancer. Hoth's CEO, Robb Knie, emphasized the patent's contribution to their diverse intellectual property portfolio, which supports continued development in oncology and dermatology therapeutics.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) reported progress on its HT-003 acne treatment, demonstrating the ability to inhibit toll-like receptor 2 (TLR2) gene expression in human keratinocytes, crucial for acne pathophysiology. The research led by Dr. Jonathan Zippin showed no toxicity at doses up to 50 µM. Future testing will focus on determining the minimal effective dose and studying HT-003's broader applications for inflammatory diseases. Hoth aims to enhance life quality for patients with dermatological disorders through innovative therapies.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has entered a Sponsored Research Agreement with George Washington University to develop a rapid diagnostic device for SARS-CoV-2. This mobile testing solution aims to provide immediate COVID-19 test results using a plasmonic system, allowing patients to detect the virus anywhere. The device has potential for significant public health impact by streamlining testing processes. Initial discussions with the FDA regarding emergency use authorization are planned for early 2021.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced that Dr. Stefanie Johns will join as Chief Scientific Officer and appears on One America News Network on September 1, 2020, at 3:00 PM ET. Dr. Johns will discuss Hoth's recent licensing of a real-time, breath-based COVID-19 mobile testing device. Hoth is a clinical-stage biopharmaceutical company focusing on therapies for dermatological disorders and has entered agreements for developing two vaccine prospects related to COVID-19.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced the appointment of Stefanie Johns, Ph.D., as Chief Scientific Officer, effective September 2020. Dr. Johns has over 8 years of experience in the biopharmaceutical and medical device sectors, having previously worked as Director of Regulatory Affairs at Enable Injections, Inc. She is expected to enhance Hoth's pipeline, particularly the pipeline slated for clinical trials in Q4 2020.
FAQ
What is the current stock price of Hoth Therapeutics (HOTH)?
What is the market cap of Hoth Therapeutics (HOTH)?
What is Hoth Therapeutics, Inc.?
What conditions does Hoth Therapeutics focus on?
What is the BioLexa Platform?
Who are some of Hoth Therapeutics' partners?
What is HT-001?
What recent advancements have been made in Alzheimer's Disease research by Hoth Therapeutics?
How is Hoth Therapeutics advancing obesity treatment?
What financial actions has Hoth Therapeutics recently taken?
What is the significance of Hoth Therapeutics' partnership with Venable, LLP?
How is artificial intelligence being used by Hoth Therapeutics?
